Track topics on Twitter Track topics that are important to you
US-based Acura Pharmaceuticals has signed a license agreement to provide its Aversion Technology to KemPharm to use with its existing and in-development immediate release (IR) opioid product candidates.
Original Article: Acura to provide Aversion Technology to KemPharmNEXT ARTICLE
Collaborations in biotechnology
Commercial and academic collaborations are used throughout the biotechnology and pharmaceutical sector to enhance research and product development. Collaborations can take the form of research and evaluation agreements, licensing, partnerships etc. ...